ClinicalTrials.gg
CompletedNCT02132949BERENICEUpdated Sep 17, 2021Results posted

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

A Phase 2 interventional study of 5-Fluorouracil and Cyclophosphamide in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 80 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
401
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
19th of 104
401 · median 100
Started
2014
with 7 others
Phase 2
59 of 104
17 open now
Registered
26th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 19th largest by enrollment, is one of 8 that started in 2014, is one of 59 in phase 2, and was the 26th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for Cohort A) will include dose-dense doxorubicin and cyclophosphamide (ddAC), followed by paclitaxel, with pertuzumab and trastuzumab given from the start of paclitaxel. Treatment regimen B (for Cohort B) will include 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), followed by docetaxel, with pertuzumab and trastuzumab given from the start of docetaxel. Participants in both cohorts will subsequently undergo surgical treatment and then resume pertuzumab and trastuzumab treatment.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants with locally advanced, inflammatory, or early-stage, unilateral, and confirmed invasive breast cancer. Participants with inflammatory breast cancer must be able to have a core needle
  • Primary tumor greater than (>) 2 centimeters (cm) in diameter, or > 5 millimeters (mm) in diameter and node-positive
  • -positive breast cancer confirmed by a central laboratory
  • Availability of tumor tissue specimen
  • Baseline greater than or equal to (>/=) 55%
  • (ECOG) performance status less than or equal to (\</=) 1
  • At least 4 weeks since major unrelated surgery, with full recovery
  • Women of and male participants with partners of childbearing potential must agree to use a "highly effective" non-hormonal form of or two "effective" forms of non-hormonal contraception by the patient and/or partner. Contraception must continue for the duration of study treatment and for at least 7 months after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • disease (Stage IV) or bilateral breast cancer
  • Participants who have had an incisional of the primary tumor or the primary tumor excised
  • Prior breast or non-breast within 5 years prior to study entry, except for carcinoma in situ and basal cell and squamous cell carcinoma of the skin. Participants with malignancies occurring more than 5 years prior to study entry are permitted if curatively treated
  • Any previous systemic therapy (including chemotherapy, immunotherapy, targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer
  • Participants with a past history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) are not allowed to enter the study if they have received any systemic therapy for its treatment or radiation therapy to the ipsilateral breast (they are allowed to enter the study if treated with surgery alone)
  • High-risk participants who have received chemopreventive drugs in the past are not allowed to enter the study
  • Inadequate bone marrow, renal, or liver function
  • History or evidence of cardiovascular condition
  • Dyspnea at rest or other diseases that require continuous oxygen therapy
  • Severe, uncontrolled systemic disease
  • Participants with poorly controlled diabetes or with evidence of diabetic vascular complications
  • Pregnancy or breast-feeding women
  • Participants who received any treatment within 4 weeks of study start
  • Participants with known infection with (HIV), virus, or virus
  • Current chronic daily treatment with (dose >10 mg methylprednisolone or equivalent [excluding inhaled steroids])
  • Known to any of the study drugs or
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab

    Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m\^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m\^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams \[mg\] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram \[mg/kg\] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.

    Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Paclitaxel · Drug: Pertuzumab · Drug: Trastuzumab

  • Experimental
    Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab

    Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m\^2 intravenously (IV) q3w, epirubicin 100mg/m\^2 IV q3w, and cyclophosphamide 600mg/m\^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m\^2 in Cycle 5, then 100mg/m\^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.

    Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Epirubicin · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.

  • Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.

  • Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.

  • Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.

  • Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.

  • Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.

  • Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.

    Also known as: Perjeta

  • Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period

    Symptomatic left ventricular systolic dysfunction (otherwise referred to as heart failure) is a serious adverse event. The NYHA Functional Classification System for Heart Failure considers the patient's symptoms: Class III: Marked limitation of physical activity; Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV: Unable to carry on any physical activity without discomfort; Symptoms of heart failure at rest; If any physical activity is undertaken, discomfort increases. The 95% CIs were calculated with the Clopper-Pearson method. Results included events with onset from first dose of pertuzumab/trastuzumab prior to surgery through the day before the first dose of any study drug after surgery. If participant withdrew without entering adjuvant period, results included all events with onset from first dose of pertuzumab/trastuzumab through 42 days after last dose of any study drug or on the day of target surgery whichever was later.

    Time frame: From day of first dose of pertuzumab or trastuzumab until the end of the neoadjuvant treatment period (as defined in the description; up to 25 weeks)

  2. Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Neoadjuvant Treatment Period

    LVEF significant decline was defined as the decline in LVEF of \>/= 10%-points from baseline to an LVEF of \< 50%. A Confirmed LVEF Significant Decline was defined as at least two consecutive readings of significant declines in LVEF. A Single LVEF Significant Decline was defined as only one reading of a significant decline (no consecutive readings) in LVEF. The category of 'At Least one LVEF Significant Decline Event' was defined as the total of confirmed and single LVEF significant declines. The 95% confidence intervals (CIs) were calculated using the Clopper-Pearson method. Results include events with onset from the first dose of pertuzumab or trastuzumab prior to surgery through the day before the first dose of any study drug after surgery. If participant withdrew without entering adjuvant period, results included all events with onset from first dose of pertuzumab or trastuzumab through 42 days after last dose of any study drug or on the day of target surgery whichever is later.

    Time frame: From day of first dose of pertuzumab or trastuzumab until the end of the neoadjuvant treatment period (as defined in the description; up to 25 weeks)

Secondary outcomes

  1. Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Adjuvant Treatment Period

    Symptomatic left ventricular systolic dysfunction (otherwise referred to as heart failure) is a serious adverse event. The NYHA Functional Classification System for Heart Failure considers the patient's symptoms: Class III: Marked limitation of physical activity; Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV: Unable to carry on any physical activity without discomfort; Symptoms of heart failure at rest; If any physical activity is undertaken, discomfort increases. The 95% CIs were calculated with the Clopper-Pearson method. Results included events with onset from the first dose of any study drug after surgery through 42 days after the last dose of any study drug.

    Time frame: From the first dose of any study drug after surgery through 42 days after the last dose of any study drug (during the adjuvant treatment period; up to approximately 39 weeks)

  2. Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Adjuvant Treatment Period

    LVEF significant decline was defined as the decline in LVEF of \>/= 10%-points from baseline to an LVEF of \< 50%. A Confirmed LVEF Significant Decline was defined as at least two consecutive readings of significant declines in LVEF. A Single LVEF Significant Decline was defined as only one reading of a significant decline (no consecutive readings) in LVEF. The category of 'At Least one LVEF Significant Decline Event' was defined as the total of confirmed and single LVEF significant declines. The 95% confidence intervals were calculated using the Clopper-Pearson method. Results included events with onset from the first dose of any study drug after surgery through 42 days after the last dose of any study drug.

    Time frame: From the first dose of any study drug after surgery through 42 days after the last dose of any study drug (during the adjuvant treatment period; up to approximately 39 weeks)

  3. Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Treatment-Free Follow-Up Period

    Symptomatic left ventricular systolic dysfunction (otherwise referred to as heart failure) is a serious adverse event. The NYHA Functional Classification System for Heart Failure considers the patient's symptoms: Class III: Marked limitation of physical activity; Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV: Unable to carry on any physical activity without discomfort; Symptoms of heart failure at rest; If any physical activity is undertaken, discomfort increases. The 95% CIs were calculated with the Clopper-Pearson method.

    Time frame: From 42 days after the last dose of study treatment until the end of treatment-free follow-up (up to 5 years)

  4. Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Treatment-Free Follow-Up Period

    LVEF significant decline was defined as the decline in LVEF of \>/= 10%-points from baseline to an LVEF of \< 50%. A Confirmed LVEF Significant Decline was defined as at least two consecutive readings of significant declines in LVEF. A Single LVEF Significant Decline was defined as only one reading of a significant decline (no consecutive readings) in LVEF. The category of 'At Least one LVEF Significant Decline Event' was defined as the total of confirmed and single LVEF significant declines. The 95% confidence intervals were calculated using the Clopper-Pearson method.

    Time frame: From 42 days after the last dose of study treatment until the end of treatment-free follow-up (up to 5 years)

  5. Overview of the Number of Participants With at Least One Adverse Event During the Neoadjuvant Period

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous with respect to an AE. Severity refers to the intensity of an AE (rated according to NCI-CTCAE v4.0 criteria or, if not listed, the following scale: Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard criteria). Severity and seriousness needed to be independently assessed for each AE that was recorded. Selected AEs for reporting included heart failure (NYHA Class II/III/IV) and asymptomatic declines in LVEF (reported as an AE with the term of ejection fraction decreased). In the results table, multiple occurrences of the same AE in one individual were counted only once. Any AE includes all serious and non-serious AEs.

    Time frame: From first dose of any study drug prior to surgery through the day before the first dose of study drug after surgery (up to 25 weeks)

  6. Overview of the Number of Participants With at Least One Adverse Event During the Adjuvant Period

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous with respect to an AE. Severity refers to the intensity of an AE (rated according to NCI-CTCAE v4.0 criteria or, if not listed, the following scale: Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard criteria). Severity and seriousness needed to be independently assessed for each AE that was recorded. Selected AEs for reporting included heart failure (NYHA Class II/III/IV) and asymptomatic declines in LVEF (reported as an AE with the term of ejection fraction decreased). In the results table, multiple occurrences of the same AE in one individual were counted only once. Any AE includes all serious and non-serious AEs.

    Time frame: From the first dose of any study drug after surgery through 42 days after the last dose of any study drug (during the adjuvant treatment period; up to approximately 39 weeks)

  7. Overview of the Number of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (rated according to NCI-CTCAE v4.0 criteria or, if not listed, the following scale: Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), and a serious AE (SAE) is a significant medical event (per standard criteria). Severity and seriousness were independently assessed for each AE. Selected AEs for reporting included heart failure (NYHA Class II/III/IV) and asymptomatic declines in LVEF (reported as ejection fraction decreased). During TFFU, only heart failure, pregnancies, and non-breast-related second primary malignancies, irrespective of causal relationship with study treatment, and drug-related SAEs were reported. Multiple occurrences of the same AE in 1 subject were counted only once.

    Time frame: From 42 days after the last dose of study treatment until the end of treatment-free follow-up (TFFU; up to 5 years)

  8. Percentage of Participants Positive for Anti-Therapeutic Antibodies (ATAs) to Pertuzumab at Baseline and Anytime Post-Baseline

    ATAs to pertuzumab in serum samples were detected using a validated bridging enzyme-linked immunosorbent assay (ELISA) method. This analysis only included participants with an ATA assay result from a baseline sample and/or at least one post-baseline sample.

    Time frame: Screening (baseline) then prior to pertuzumab infusion (Hour 0) in Cycles 5, 14, 18 thereafter anytime between Cycle 8 Day 21 and surgery, up to treatment completion visit (cycle length=2-3 weeks; up to approximately 1 year, 3 months)

  9. Percentage of Participants With Total Pathologic Complete Response (tpCR), Evaluated After Surgery

    Total pathologic complete response (tpCR) was the pCR based on tumor and nodal staging (i.e., histological confirmation of pCR in breast and nodes at surgery) and was defined as the absence of any residual invasive cancer in the breast and the absence of any metastatic cells in the regional lymph nodes (i.e., ypT0/is ypN0 tpCR). Participants who did not undergo surgery or did not have a valid pCR assessment were considered non-responders in the analysis. The 95% CIs were calculated using the Clopper-Pearson method.

    Time frame: After completion of neoadjuvant treatment and surgery (up to 25 weeks)

  10. Percentage of Participants With Clinical Response as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 During the Neoadjuvant Treatment Period

    The clinical response rate was defined as the percentage of participants in the ITT population who achieved a complete response (CR) or partial response (PR) prior to surgery, according to RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter compared to Baseline. Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient (20%) increase to qualify for disease progression, in addition to no new target lesions. Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter, taking as reference the smallest sum of the longest diameter observed at previous tumor assessment, or the appearance of any new lesions. Participants were classified as missing or unevaluable if no assessments were measured prior to surgery on the ipsilateral breast. The 95% CIs were calculated using the Clopper-Pearson method; they were only calculated for responses (not for missing or unevaluable data).

    Time frame: From Baseline until disease progression or death due to any cause up to 24 weeks (during the neoadjuvant treatment period; assessed on Day 1 of Cycles 1-8 [cycle length=2-3 weeks])

  11. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1 to 5 Years, Determined by the Investigator According to RECIST v1.1

    The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Event-free survival (EFS) was defined as the time from enrollment to the first occurrence of progressive disease (PD), relapse, or death from any cause, with tumor evaluations performed by the investigator according to RECIST v1.1. Ipsilateral or contralateral in situ disease and second primary non-breast cancers (including in situ carcinomas and non-melanoma skin cancers) were not counted as progressive disease or relapse. Participants who withdrew from the study without documented progression or relapse and for whom there existed evidence that evaluations had been made, were censored at the date of the last assessment at which the participant was known to be free from progressive disease or relapse. Participants with no tumor evaluations after baseline were censored at the date of enrollment plus 1 day.

    Time frame: At 1, 2, 3, 4, and 5 years

  12. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Invasive Disease-Free Survival (iDFS) at 1 to 4 Years, Determined by the Investigator According to RECIST v1.1

    The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Invasive disease-free survival (iDFS) was defined as the time from the first date of no disease (the date of surgery) to the first documentation of progressive invasive disease, relapse, or death, with tumor evaluations performed by the investigator according to RECIST v1.1. Ipsilateral or contralateral in situ disease and second primary non-breast cancers (including in situ carcinomas and non-melanoma skin cancers) were not counted as progressive disease or relapse. Participants who withdrew from the study without documented progression or relapse and for whom there existed evidence that evaluations had been made, were censored at the date of the last assessment at which the participant was known to be alive and disease-free. Participants with no postbaseline information and participants who did not undergo surgery were excluded from the analysis.

    Time frame: At 1, 2, 3, and 4 years

  13. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1 to 5 Years

    The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Overall survival (OS) was defined as the time from enrollment to death from any cause. Participants who were alive or lost to follow-up were censored at their last known date in the study. Participants with no post-baseline assessments were censored at the date of enrollment plus 1 day.

    Time frame: At 1, 2, 3, 4, and 5 years

07

Results

Posted Apr 13, 2017

Participant flow

Participant flow — Overall Study
MilestoneCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Started199201
Received any cohort a study treatment1981
Received any cohort b study treatment0198
Underwent surgery187194
Completed neoadjuvant treatment (25 weeks)182189
Started adjuvant treatment181190
Completed adjuvant treatment (up to 39 weeks)163176
Started treatment-free follow-up (up to 5 years)195195
Completed158173
Not completed4128
Withdrew: Death713
Withdrew: Lost to follow-up144
Withdrew: Withdrawal by subject65
Withdrew: Noncompliance51
Withdrew: Physician decision31
Withdrew: Disease progression30
Withdrew: Adverse event21
Withdrew: Withdrew prior to treatment12
Withdrew: Reason unspecified01

Outcome measures

PrimaryPercentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period

Symptomatic left ventricular systolic dysfunction (otherwise referred to as heart failure) is a serious adverse event. The NYHA Functional Classification System for Heart Failure considers the patient's symptoms: Class III: Marked limitation of physical activity; Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV: Unable to carry on any physical activity without discomfort; Symptoms of heart failure at rest; If any physical activity is undertaken, discomfort increases. The 95% CIs were calculated with the Clopper-Pearson method. Results included events with onset from first dose of pertuzumab/trastuzumab prior to surgery through the day before the first dose of any study drug after surgery. If participant withdrew without entering adjuvant period, results included all events with onset from first dose of pertuzumab/trastuzumab through 42 days after last dose of any study drug or on the day of target surgery whichever was later.

Time frame:
From day of first dose of pertuzumab or trastuzumab until the end of the neoadjuvant treatment period (as defined in the description; up to 25 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period
percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period1.5 (0.31 to 4.34)0 (0.00 to 1.85)
PrimaryPercentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Neoadjuvant Treatment Period

LVEF significant decline was defined as the decline in LVEF of \>/= 10%-points from baseline to an LVEF of \< 50%. A Confirmed LVEF Significant Decline was defined as at least two consecutive readings of significant declines in LVEF. A Single LVEF Significant Decline was defined as only one reading of a significant decline (no consecutive readings) in LVEF. The category of 'At Least one LVEF Significant Decline Event' was defined as the total of confirmed and single LVEF significant declines. The 95% confidence intervals (CIs) were calculated using the Clopper-Pearson method. Results include events with onset from the first dose of pertuzumab or trastuzumab prior to surgery through the day before the first dose of any study drug after surgery. If participant withdrew without entering adjuvant period, results included all events with onset from first dose of pertuzumab or trastuzumab through 42 days after last dose of any study drug or on the day of target surgery whichever is later.

Time frame:
From day of first dose of pertuzumab or trastuzumab until the end of the neoadjuvant treatment period (as defined in the description; up to 25 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Neoadjuvant Treatment Period
percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
At Least One LVEF Significant Decline Event (Confirmed+Single)6.5 (3.5 to 10.9)2.0 (0.6 to 5.1)
At Least One Confirmed LVEF Significant Decline1.0 (0.1 to 3.6)0.5 (0.0 to 2.8)
At Least One Single LVEF Significant Decline5.5 (2.8 to 9.7)1.5 (0.3 to 4.4)
SecondaryPercentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Adjuvant Treatment Period

Symptomatic left ventricular systolic dysfunction (otherwise referred to as heart failure) is a serious adverse event. The NYHA Functional Classification System for Heart Failure considers the patient's symptoms: Class III: Marked limitation of physical activity; Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV: Unable to carry on any physical activity without discomfort; Symptoms of heart failure at rest; If any physical activity is undertaken, discomfort increases. The 95% CIs were calculated with the Clopper-Pearson method. Results included events with onset from the first dose of any study drug after surgery through 42 days after the last dose of any study drug.

Time frame:
From the first dose of any study drug after surgery through 42 days after the last dose of any study drug (during the adjuvant treatment period; up to approximately 39 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Adjuvant Treatment Period
Percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Adjuvant Treatment Period0 (0.00 to 2.02)0.5 (0.01 to 2.90)
SecondaryPercentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Adjuvant Treatment Period

LVEF significant decline was defined as the decline in LVEF of \>/= 10%-points from baseline to an LVEF of \< 50%. A Confirmed LVEF Significant Decline was defined as at least two consecutive readings of significant declines in LVEF. A Single LVEF Significant Decline was defined as only one reading of a significant decline (no consecutive readings) in LVEF. The category of 'At Least one LVEF Significant Decline Event' was defined as the total of confirmed and single LVEF significant declines. The 95% confidence intervals were calculated using the Clopper-Pearson method. Results included events with onset from the first dose of any study drug after surgery through 42 days after the last dose of any study drug.

Time frame:
From the first dose of any study drug after surgery through 42 days after the last dose of any study drug (during the adjuvant treatment period; up to approximately 39 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Adjuvant Treatment Period
percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
At Least One LVEF Significant Decline Event (Confirmed+Single)7.7 (4.3 to 12.6)10.5 (6.5 to 15.8)
At Least One Confirmed LVEF Significant Decline2.8 (0.9 to 6.3)3.2 (1.2 to 6.7)
At Least One Single LVEF Significant Decline5.0 (2.3 to 9.2)7.4 (4.1 to 12.1)
SecondaryPercentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Treatment-Free Follow-Up Period

Symptomatic left ventricular systolic dysfunction (otherwise referred to as heart failure) is a serious adverse event. The NYHA Functional Classification System for Heart Failure considers the patient's symptoms: Class III: Marked limitation of physical activity; Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV: Unable to carry on any physical activity without discomfort; Symptoms of heart failure at rest; If any physical activity is undertaken, discomfort increases. The 95% CIs were calculated with the Clopper-Pearson method.

Time frame:
From 42 days after the last dose of study treatment until the end of treatment-free follow-up (up to 5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Treatment-Free Follow-Up Period
Percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Treatment-Free Follow-Up Period0 (0.00 to 1.84)0.5 (0.01 to 2.78)
SecondaryPercentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Treatment-Free Follow-Up Period

LVEF significant decline was defined as the decline in LVEF of \>/= 10%-points from baseline to an LVEF of \< 50%. A Confirmed LVEF Significant Decline was defined as at least two consecutive readings of significant declines in LVEF. A Single LVEF Significant Decline was defined as only one reading of a significant decline (no consecutive readings) in LVEF. The category of 'At Least one LVEF Significant Decline Event' was defined as the total of confirmed and single LVEF significant declines. The 95% confidence intervals were calculated using the Clopper-Pearson method.

Time frame:
From 42 days after the last dose of study treatment until the end of treatment-free follow-up (up to 5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Treatment-Free Follow-Up Period
Percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
At Least One LVEF Significant Decline Event (Confirmed+Single)6.0 (3.2 to 10.3)3.5 (1.4 to 7.1)
At Least One Confirmed LVEF Significant Decline3.0 (1.1 to 6.4)1.0 (0.1 to 3.6)
At Least One Single LVEF Significant Decline3.0 (1.1 to 6.4)2.5 (0.8 to 5.8)
SecondaryOverview of the Number of Participants With at Least One Adverse Event During the Neoadjuvant Period

An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous with respect to an AE. Severity refers to the intensity of an AE (rated according to NCI-CTCAE v4.0 criteria or, if not listed, the following scale: Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard criteria). Severity and seriousness needed to be independently assessed for each AE that was recorded. Selected AEs for reporting included heart failure (NYHA Class II/III/IV) and asymptomatic declines in LVEF (reported as an AE with the term of ejection fraction decreased). In the results table, multiple occurrences of the same AE in one individual were counted only once. Any AE includes all serious and non-serious AEs.

Time frame:
From first dose of any study drug prior to surgery through the day before the first dose of study drug after surgery (up to 25 weeks)
Reported as:
Count of participants · Participants
Overview of the Number of Participants With at Least One Adverse Event During the Neoadjuvant Period
ParticipantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Any Adverse Event (AE)198198
NCI-CTCAE Grade 3-5 AE99108
Serious AE4552
Deaths00
Ejection Fraction Decreased (Any Grade)147
Heart Failure (Any Grade)40
SecondaryOverview of the Number of Participants With at Least One Adverse Event During the Adjuvant Period

An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous with respect to an AE. Severity refers to the intensity of an AE (rated according to NCI-CTCAE v4.0 criteria or, if not listed, the following scale: Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard criteria). Severity and seriousness needed to be independently assessed for each AE that was recorded. Selected AEs for reporting included heart failure (NYHA Class II/III/IV) and asymptomatic declines in LVEF (reported as an AE with the term of ejection fraction decreased). In the results table, multiple occurrences of the same AE in one individual were counted only once. Any AE includes all serious and non-serious AEs.

Time frame:
From the first dose of any study drug after surgery through 42 days after the last dose of any study drug (during the adjuvant treatment period; up to approximately 39 weeks)
Reported as:
Count of participants · Participants
Overview of the Number of Participants With at Least One Adverse Event During the Adjuvant Period
ParticipantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Any Adverse Event (AE)171171
NCI-CTCAE Grade 3-5 AE2340
Serious AE1517
Deaths00
Ejection Fraction Decreased (Any Grade)1520
Heart Failure (Any Grade)02
SecondaryOverview of the Number of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period

An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (rated according to NCI-CTCAE v4.0 criteria or, if not listed, the following scale: Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), and a serious AE (SAE) is a significant medical event (per standard criteria). Severity and seriousness were independently assessed for each AE. Selected AEs for reporting included heart failure (NYHA Class II/III/IV) and asymptomatic declines in LVEF (reported as ejection fraction decreased). During TFFU, only heart failure, pregnancies, and non-breast-related second primary malignancies, irrespective of causal relationship with study treatment, and drug-related SAEs were reported. Multiple occurrences of the same AE in 1 subject were counted only once.

Time frame:
From 42 days after the last dose of study treatment until the end of treatment-free follow-up (TFFU; up to 5 years)
Reported as:
Count of participants · Participants
Overview of the Number of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period
ParticipantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Any Adverse Event (AE)37
NCI-CTCAE Grade 3-5 AE25
Serious AE37
Deaths713
Ejection Fraction Decreased (Any Grade)11
Heart Failure (Any Grade)01
SecondaryPercentage of Participants Positive for Anti-Therapeutic Antibodies (ATAs) to Pertuzumab at Baseline and Anytime Post-Baseline

ATAs to pertuzumab in serum samples were detected using a validated bridging enzyme-linked immunosorbent assay (ELISA) method. This analysis only included participants with an ATA assay result from a baseline sample and/or at least one post-baseline sample.

Time frame:
Screening (baseline) then prior to pertuzumab infusion (Hour 0) in Cycles 5, 14, 18 thereafter anytime between Cycle 8 Day 21 and surgery, up to treatment completion visit (cycle length=2-3 weeks; up to approximately 1 year, 3 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Positive for Anti-Therapeutic Antibodies (ATAs) to Pertuzumab at Baseline and Anytime Post-Baseline
Percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
At Baseline1.62.1
Anytime Post-Baseline4.63.6
SecondaryPercentage of Participants With Total Pathologic Complete Response (tpCR), Evaluated After Surgery

Total pathologic complete response (tpCR) was the pCR based on tumor and nodal staging (i.e., histological confirmation of pCR in breast and nodes at surgery) and was defined as the absence of any residual invasive cancer in the breast and the absence of any metastatic cells in the regional lymph nodes (i.e., ypT0/is ypN0 tpCR). Participants who did not undergo surgery or did not have a valid pCR assessment were considered non-responders in the analysis. The 95% CIs were calculated using the Clopper-Pearson method.

Time frame:
After completion of neoadjuvant treatment and surgery (up to 25 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Total Pathologic Complete Response (tpCR), Evaluated After Surgery
Percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Percentage of Participants With Total Pathologic Complete Response (tpCR), Evaluated After Surgery61.8 (54.67 to 68.59)60.7 (53.58 to 67.49)
SecondaryPercentage of Participants With Clinical Response as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 During the Neoadjuvant Treatment Period

The clinical response rate was defined as the percentage of participants in the ITT population who achieved a complete response (CR) or partial response (PR) prior to surgery, according to RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter compared to Baseline. Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient (20%) increase to qualify for disease progression, in addition to no new target lesions. Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter, taking as reference the smallest sum of the longest diameter observed at previous tumor assessment, or the appearance of any new lesions. Participants were classified as missing or unevaluable if no assessments were measured prior to surgery on the ipsilateral breast. The 95% CIs were calculated using the Clopper-Pearson method; they were only calculated for responses (not for missing or unevaluable data).

Time frame:
From Baseline until disease progression or death due to any cause up to 24 weeks (during the neoadjuvant treatment period; assessed on Day 1 of Cycles 1-8 [cycle length=2-3 weeks])
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 During the Neoadjuvant Treatment Period
Percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
Clinical Response Rate (CR+PR)67.3 (60.35 to 73.80)60.2 (53.07 to 67.02)
Complete Response (CR)39.7 (32.85 to 46.86)23.9 (18.16 to 30.39)
Partial Response (PR)27.6 (21.55 to 34.41)36.3 (29.67 to 43.38)
Stable Disease (SD)7.0 (3.90 to 11.52)10.0 (6.18 to 14.95)
Progressive Disease (PD)0.5 (0.01 to 2.77)1.0 (0.12 to 3.55)
Missing or Unevaluable25.1 (NA to NA)28.9 (NA to NA)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1 to 5 Years, Determined by the Investigator According to RECIST v1.1

The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Event-free survival (EFS) was defined as the time from enrollment to the first occurrence of progressive disease (PD), relapse, or death from any cause, with tumor evaluations performed by the investigator according to RECIST v1.1. Ipsilateral or contralateral in situ disease and second primary non-breast cancers (including in situ carcinomas and non-melanoma skin cancers) were not counted as progressive disease or relapse. Participants who withdrew from the study without documented progression or relapse and for whom there existed evidence that evaluations had been made, were censored at the date of the last assessment at which the participant was known to be free from progressive disease or relapse. Participants with no tumor evaluations after baseline were censored at the date of enrollment plus 1 day.

Time frame:
At 1, 2, 3, 4, and 5 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1 to 5 Years, Determined by the Investigator According to RECIST v1.1
Estimate of percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
1 Year98.47 (96.75 to 100.00)97.48 (95.29 to 99.66)
2 Years95.80 (92.94 to 98.65)92.86 (89.25 to 96.46)
3 Years93.58 (90.06 to 97.10)90.78 (86.72 to 94.84)
4 Years92.39 (88.55 to 96.23)89.73 (85.47 to 94.00)
5 Years90.84 (86.48 to 95.20)89.20 (84.84 to 93.57)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Invasive Disease-Free Survival (iDFS) at 1 to 4 Years, Determined by the Investigator According to RECIST v1.1

The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Invasive disease-free survival (iDFS) was defined as the time from the first date of no disease (the date of surgery) to the first documentation of progressive invasive disease, relapse, or death, with tumor evaluations performed by the investigator according to RECIST v1.1. Ipsilateral or contralateral in situ disease and second primary non-breast cancers (including in situ carcinomas and non-melanoma skin cancers) were not counted as progressive disease or relapse. Participants who withdrew from the study without documented progression or relapse and for whom there existed evidence that evaluations had been made, were censored at the date of the last assessment at which the participant was known to be alive and disease-free. Participants with no postbaseline information and participants who did not undergo surgery were excluded from the analysis.

Time frame:
At 1, 2, 3, and 4 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Invasive Disease-Free Survival (iDFS) at 1 to 4 Years, Determined by the Investigator According to RECIST v1.1
Estimate of percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
1 Year98.91 (97.41 to 100.00)96.34 (93.68 to 99.00)
2 Years95.57 (92.57 to 98.57)94.25 (90.94 to 97.55)
3 Years94.42 (91.06 to 97.78)91.06 (87.00 to 95.11)
4 Years92.60 (88.72 to 96.48)91.06 (87.00 to 95.11)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1 to 5 Years

The Kaplan-Meier method was used to estimate the percentage of participants who were event-free at landmark timepoints. Overall survival (OS) was defined as the time from enrollment to death from any cause. Participants who were alive or lost to follow-up were censored at their last known date in the study. Participants with no post-baseline assessments were censored at the date of enrollment plus 1 day.

Time frame:
At 1, 2, 3, 4, and 5 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1 to 5 Years
Estimate of percentage of participantsCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
1 Year99.48 (98.48 to 100.00)100.00 (100.00 to 100.00)
2 Years98.96 (97.52 to 100.00)97.94 (95.94 to 99.94)
3 Years97.86 (95.78 to 99.94)96.38 (93.74 to 99.01)
4 Years97.86 (95.78 to 99.94)94.81 (91.68 to 97.94)
5 Years96.10 (93.26 to 98.94)93.75 (90.33 to 97.17)

Adverse events

Collected over From first dose of any study drug until the end of treatment-free follow-up (up to 6 years, 1 month). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab7/199 (3.5%)56/199 (28.1%)197/199 (99%)
Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab13/198 (6.6%)66/198 (33.3%)198/198 (100%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
FEBRILE NEUTROPENIABlood and lymphatic system disorders11/19927/198
DIARRHOEAGastrointestinal disorders1/19911/198
NEUTROPENIC SEPSISInfections and infestations0/1997/198
EJECTION FRACTION DECREASEDInvestigations5/1995/198
CARDIAC FAILURECardiac disorders3/1994/198
PYREXIAGeneral disorders1/1994/198
VASCULAR DEVICE INFECTIONInfections and infestations2/1993/198
DEVICE RELATED INFECTIONInfections and infestations3/1990/198
URINARY TRACT INFECTIONInfections and infestations3/1990/198
NEUTROPENIABlood and lymphatic system disorders1/1992/198
Most frequent other events
Showing 10 of 102
Most frequent other events
EventCohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab
NAUSEAGastrointestinal disorders144/199142/198
DIARRHOEAGastrointestinal disorders143/199141/198
ALOPECIASkin and subcutaneous tissue disorders127/199117/198
FATIGUEGeneral disorders125/19981/198
ASTHENIAGeneral disorders41/19985/198
CONSTIPATIONGastrointestinal disorders73/19978/198
MUCOSAL INFLAMMATIONGeneral disorders46/19977/198
MYALGIAMusculoskeletal and connective tissue disorders49/19976/198
ARTHRALGIAMusculoskeletal and connective tissue disorders73/19967/198
VOMITINGGastrointestinal disorders46/19971/198

Baseline characteristics

Intent to treat (ITT) population included all participants who were enrolled regardless of whether they received any study treatment. One participant in Cohort B who was HER2 negative and was enrolled by error was excluded from the ITT population.

Age, Continuous
Age, Continuous(years)Cohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, TrastuzumabTotal
Mean49.8 ± 11.749.5 ± 11.549.6 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, TrastuzumabTotal
Female199200399
Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, TrastuzumabTotal
Hispanic or Latino244670
Not Hispanic or Latino147114261
Unknown or Not Reported284169
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: ddAC, Paclitaxel, Pertuzumab, TrastuzumabCohort B: FEC, Docetaxel, Pertuzumab, TrastuzumabTotal
American Indian or Alaska Native606
Asian549
Native Hawaiian or Other Pacific Islander000
Black or African American11011
White162163325
More than one race000
Unknown or Not Reported153449
08

Study locations

80 sites
  • University of South Alabama; Mitchell Cancer Institute
    Mobile, Alabama 36604, United States
  • Marin Specialty Care
    Greenbrae, California 94904, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
    Washington, District of Columbia 20007, United States
  • Washington Cancer Institute at MedStar Washington Hospital Center.
    Washington, District of Columbia 20010, United States
  • Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
    Jacksonville, Florida 32256, United States
  • Northwest Georgia Oncology Centers PC - Marietta
    Marietta, Georgia 30060, United States
  • Berkshire Medical Center
    Pittsfield, Massachusetts 01201, United States
  • Allina Health, Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • Saint Lukes Hospital Cancer Institute
    Kansas City, Missouri 64111, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Regional Cancer Care Associates LLC - Morristown
    Morristown, New Jersey 07962, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • MSKCC @ Commack
    Commack, New York 11725, United States
  • MSKCC @ West Harrison
    Harrison, New York 10604, United States
  • Mount Sinai Beth Israel Comprehensive Cancer Center
    New York, New York 10011, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • MSKC @ Rockville
    Rockville Centre, New York 11570, United States
  • Mercy Clinic Oklahoma Communties, Inc
    Oklahoma City, Oklahoma 73120, United States
  • Harrington Cancer Center
    Amarillo, Texas 79106, United States
  • University of Utah; Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
  • PeaceHealth St. Joseph Cancer Center
    Bellingham, Washington 98225, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Horizon Health Network
    Moncton, New Brunswick E1C 6Z8, Canada
  • Royal Victoria Hospital
    Barrie, Ontario L4M 6M2, Canada
  • Cite de La Sante de Laval; Hemato-Oncologie
    Laval, Quebec H7M 3L9, Canada
  • St Mary's Hospital Center
    Montreal, Quebec H3T1M5, Canada
  • Hopital Sacre-Coeur Research Centre
    Montreal, Quebec H4J 1C5, Canada
  • Allan Blair Cancer Centre
    Regina, Saskatchewan S4T 7T1, Canada
  • Herlev Hospital; Afdeling for Kræftbehandling
    Herlev, 2730, Denmark
  • Rigshospitalet; Onkologisk Klinik
    København Ø, 2100, Denmark
  • Vejle Sygehus; Onkologisk Afdeling
    Vejle, 7100, Denmark
  • Clinique Victor Hugo; Chimiotherapie
    Le Mans, 72015, France
  • Centre Oscar Lambret; Cancerologie Gynecologique
    Lille, 59020, France
  • Centre Leon Berard; Departement Oncologie Medicale
    Lyon, 69373, France
  • Clinique Clementville; Hopital De Jour
    Montpellier, 34070, France
  • Centre D'Oncologie de Gentilly; Oncology
    Nancy, 54100, France
  • Centre Antoine Lacassagne; Hopital De Jour A2
    Nice, 06189, France
  • Institut Curie; Oncologie Medicale
    Paris, 75231, France
  • Centre Eugene Marquis; Unite Huguenin
    Rennes, 35042, France
  • Institut Gustave Roussy; Departement Oncologie Medicale
    Villejuif, 94805, France
  • Universitätsklinikum "Carl Gustav Carus"; Frauenheilkunde und Geburtshilfe
    Dresden, 01307, Germany
  • Dres.Andreas Ammon und Dirk Meyer
    Göttingen, 37073, Germany
  • Dres. Andreas Köhler und Roswitha Fuchs
    Langen, 63225, Germany
  • Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde
    München, 81675, Germany
  • Ruppiner Kliniken, Klinik fuer Gynaekologie und Geburtshilfe
    Neuruppin, 16816, Germany
  • Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche
    Roma, Lazio 00161, Italy
  • A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica
    Torino, Piemonte 10126, Italy
  • Asl Le-Ospedale "Vito Fazzi";U.O. Oncologia
    Lecce, Puglia 73100, Italy
  • Casa Di Cura Di Alta Specialita La Maddalena; Dept. Oncologico Di Iii Livello
    Palermo, Sicilia 90146, Italy
  • Ospedale Santa Maria Annunziata; Oncologia
    Bagno a Ripoli, Toscana 50012, Italy
  • Ospedale Della Misericordia; U.O. Di Medicina Ia - Oncologia Medica
    Grosseto, Toscana 58100, Italy
  • Iem-Fucam
    D.f., 04980, Mexico
  • Centro de Diagnóstico y Tratamiento Integral de Mama, Hospital San José Tec de Monterrey
    Monterrey, 64710, Mexico
  • Haukeland Universitetssjukehus; Klinisk forskningspost
    Bergen, 5021, Norway
  • Oslo universitetssykehus HF, Ullevål, Kreftsenteret
    Oslo, 0450, Norway
  • Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej
    Bialystok, 15-027, Poland
  • Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
    Kraków, 30-688, Poland
  • Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii
    Otwock, 05-400, Poland
  • Wielkopolskie Centrum Onkologii; im. Marii Skłodowskiej-Curie
    Poznan, 61-866, Poland
  • Centro Clinico Champalimaud; Oncologia Medica
    Lisboa, 1400-038, Portugal
  • Hospital de Santa Maria; Servico de Oncologia Medica
    Lisboa, 1649-035, Portugal
  • Hospital Beatriz Angelo; Departamento de Oncologia
    Loures, 2674-514, Portugal
  • IPO do Porto; Servico de Oncologia Medica
    Porto, 4200-072, Portugal
  • Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
    Córdoba, Cordoba 14004, Spain
  • Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia
    La Coruña, 15009, Spain
  • Hospital Universitario de la Princesa; Servicio de Oncologia
    Madrid, 28006, Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
    Madrid, 28034, Spain
  • Hospital Universitario Virgen Macarena; Servicio de Oncologia
    Sevilla, 41009, Spain
  • Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
    Toledo, 45004, Spain
  • Royal United Hospital; Oncology Department
    Bath, BA1 3NG, United Kingdom
  • Royal Bournemouth Hospital; Oncology
    Bournemouth, BH7 7DW, United Kingdom
  • Guys & St Thomas Hospital; Department of Oncology
    London, SE1 9RT, United Kingdom
  • Royal Marsden Hospital - Fulham; Oncology Department
    London, SW3 6JJ, United Kingdom
  • Freeman Hospital; Northern Centre For Cancer Care
    New Castle Upon Tyne, NE7 7DN, United Kingdom
  • Churchill Hospital; Oxford Cancer and Haematology Centre
    Oxford, OX3 7LJ, United Kingdom
  • Peterborough City Hospital, Edith Cavell Campus; Oncology Department
    Peterborough, PE3 9GZ, United Kingdom
  • Royal Marsden Hospital; Dept of Medical Oncology
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773. PubMed 29253081 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Mar 2016, 19 months.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 19 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2014
First posted
May 7, 2014
StartActual
Jul 14, 2014
Primary completionActual
Mar 3, 2016
CompletionActual
Aug 25, 2020
Results first posted
Apr 13, 2017
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02132949
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 7, 2014
Start date
Jul 14, 2014
Primary completion
Mar 3, 2016
Completion
Aug 25, 2020
Results posted
Apr 13, 2017
Last update
Sep 17, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pertuzumab · Trastuzumab

Start the discussion